Duloxetine
Product Images NDC 55700-605

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 55700-605). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quality Care Products Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (New Doc 2018 04 18 1)

Label for Duloxetine DR 30 mg capsules, packaged and distributed by Quality Care Products LLC. The label indicates 30 capsules per package and states each capsule contains enteric-coated pellets of 33.7 mg Duloxetine Hydrochloride USP equivalent to 30 mg Duloxetine. Manufactured by Ajanta Pharma Limited, India. The label includes NDC 55700-0605-30 and storage warnings.*

FDA Label Image

Figure01 (Duloxetine Fig01)

A line graph depicting the proportion of patients with relapse over time in days from randomization. The graph compares the relapse rates between placebo treatment, shown as a dashed line, and Duloxetine treatment, shown as a solid line, over a period of up to 200 days.*

FDA Label Image

Figure2 (Duloxetine Fig02)

A Kaplan-Meier curve chart comparing the proportion of patients with relapse over time from randomization to relapse (in days) between Duloxetine and placebo treatments. The graph shows separate relapse rates for Duloxetine and placebo groups over approximately 250 days.*

FDA Label Image

Figure04 (Duloxetine Fig04)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and Placebo, showing a higher percentage of patients improved at various pain improvement levels for Duloxetine compared to placebo.*

FDA Label Image

Figure07 (Duloxetine Fig07)

A line graph comparing the percentage of patients improved by percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60/120 mg once daily. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. Two lines track patient improvement across various pain reduction thresholds for placebo and Duloxetine treatment groups.*

FDA Label Image

Figure08 (Duloxetine Fig08)

A line graph comparing the percentage of patients improved by percent improvement in pain from baseline for Duloxetine 60 mg once daily versus placebo. The x-axis displays percent improvement in pain from 0 to 100%, and the y-axis shows percentage of patients improved from 0 to 100%. The graph includes markers for Duloxetine (solid diamonds) and placebo (crosses) with vertical dotted lines at 30% and 50% improvement thresholds.*

FDA Label Image

Figure09 (Duloxetine Fig09)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline (BOCF) comparing placebo and Duloxetine 60/120 mg once daily. The graph shows two lines: one for placebo with lower patient improvement percentages and one for Duloxetine with higher improvement percentages across pain improvement levels from 0 to 100%.*

FDA Label Image

Duloxetine-structure (Duloxetine Structure)

Chemical structure of duloxetine hydrochloride showing a fused aromatic system with a thiophene ring and a chiral center attached to an amine hydrochloride group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.